تقرير
Safety and efficacy of a programmed cell death 1 inhibitor combined with oxaliplatin plus S-1 in patients with Borrmann large type III and IV gastric cancers.
| العنوان: | Safety and efficacy of a programmed cell death 1 inhibitor combined with oxaliplatin plus S-1 in patients with Borrmann large type III and IV gastric cancers. |
|---|---|
| المؤلفون: | Bao ZH; Department of Interventional Radiology, Zhejiang Cancer Hospital, Hangzhou 310004, Zhejiang Province, China., Hu C; Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang Province, China., Zhang YQ; Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang Province, China., Yu PC; Department of Colonic Surgery, Jinhua Central Hospital, Jinhua 321000, Zhejiang Province, China., Wang Y; Department of Breast Surgery, Lin'an People's Hospital, Hangzhou 311300, Zhejiang Province, China., Xu ZY; Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang Province, China., Fu HY; Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang Province, China., Cheng XD; Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang Province, China. chengxd@zjcc.org.cn. |
| المصدر: | World journal of gastrointestinal oncology [World J Gastrointest Oncol] 2024 Apr 15; Vol. 16 (4), pp. 1281-1295. |
| نوع المنشور: | Clinical Trial |
| اللغة: | English |
| بيانات الدورية: | Publisher: Baishideng Publishing Group Country of Publication: China NLM ID: 101532470 Publication Model: Print Cited Medium: Print ISSN: 1948-5204 (Print) NLM ISO Abbreviation: World J Gastrointest Oncol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: 2014- : Pleasanton, CA : Baishideng Publishing Group Original Publication: Beijing, China : Baishideng |
| مستخلص: | Background: Gastric cancer (GC) is the fifth most common and the fourth most lethal malignant tumour in the world. Most patients are already in the advanced stage when they are diagnosed, which also leads to poor overall survival. The effect of postoperative adjuvant chemotherapy for advanced GC is unsatisfactory with a high rate of distant metastasis and local recurrence. Aim: To investigate the safety and efficacy of a programmed cell death 1 (PD-1) inhibitor combined with oxaliplatin and S-1 (SOX) in the treatment of Borrmann large type III and IV GCs. Methods: A retrospective analysis (IRB-2022-371) was performed on 89 patients with Borrmann large type III and IV GCs who received neoadjuvant therapy (NAT) from January 2020 to December 2021. According to the different neoadjuvant treatment regimens, the patients were divided into the SOX group (61 patients) and the PD-1 + SOX (P-SOX) group (28 patients). Results: The pathological response (tumor regression grade 0/1) in the P-SOX group was significantly higher than that in the SOX group (42.86% vs 18.03%, P = 0.013). The incidence of ypN0 in the P-SOX group was higher than that in the SOX group (39.29% vs 19.67%, P = 0.05). The use of PD-1 inhibitors was an independent factor affecting tumor regression grade. Meanwhile, the use of PD-1 did not increase postoperative complications or the adverse effects of NAT. Conclusion: A PD-1 inhibitor combined with SOX could significantly improve the rate of tumour regression during NAT for patients with Borrmann large type III and IV GCs. Competing Interests: Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article. (©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.) |
| References: | World J Gastroenterol. 2008 Feb 28;14(8):1149-55. (PMID: 18300338) Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774) Future Oncol. 2019 Mar;15(9):943-952. (PMID: 30777447) Bull Cancer. 2020 Apr;107(4):438-446. (PMID: 32057467) CMAJ. 2020 Jun 15;192(24):E651. (PMID: 32540906) Front Immunol. 2022 Jan 18;12:783243. (PMID: 35116023) J Hematol Oncol. 2018 Feb 27;11(1):31. (PMID: 29482595) J Gastrointest Surg. 2021 Jun;25(6):1380-1387. (PMID: 32542556) Nature. 2014 Sep 11;513(7517):202-9. (PMID: 25079317) Clin Cancer Res. 2021 Jun 1;27(11):3069-3078. (PMID: 33766817) Cancer Epidemiol Biomarkers Prev. 2020 Feb;29(2):414-419. (PMID: 31719065) Front Oncol. 2021 Aug 06;11:683608. (PMID: 34422637) Nat Rev Clin Oncol. 2011 Jun 07;8(8):450-2. (PMID: 21647192) World J Gastroenterol. 2015 Jun 28;21(24):7343-8. (PMID: 26139980) Zhonghua Zhong Liu Za Zhi. 2003 May;25(3):278-81. (PMID: 12839695) PLoS One. 2018 Jan 25;13(1):e0189294. (PMID: 29370182) J Clin Oncol. 2019 Dec 10;37(35):3392-3400. (PMID: 31513484) BMC Gastroenterol. 2017 Mar 14;17(1):41. (PMID: 28292272) CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338) Acta Pathol Jpn. 1964 Jan;14:85-7. (PMID: 14196559) J Clin Oncol. 2011 May 1;29(13):1715-21. (PMID: 21444866) World J Surg Oncol. 2020 Aug 13;18(1):204. (PMID: 32792016) Oncotarget. 2017 Feb 21;8(8):13320-13328. (PMID: 28076847) Gastric Cancer. 2021 Mar;24(2):492-502. (PMID: 33200303) Oncotarget. 2014 Dec 15;5(23):12189-202. (PMID: 25361008) Pathol Res Pract. 2020 Apr;216(4):152881. (PMID: 32089413) Blood. 2020 Nov 19;136(21):2401-2409. (PMID: 32730586) N Engl J Med. 2006 Jul 6;355(1):11-20. (PMID: 16822992) Gut. 2009 Jan;58(1):127-43. (PMID: 19091831) JAMA Oncol. 2017 Sep 01;3(9):1237-1244. (PMID: 28448662) World J Gastrointest Oncol. 2020 Jan 15;12(1):37-53. (PMID: 31966912) Chin J Cancer Res. 2019 Feb;31(1):117-134. (PMID: 30996570) CA Cancer J Clin. 2012 Sep-Oct;62(5):309-35. (PMID: 22576456) N Engl J Med. 2022 May 26;386(21):1973-1985. (PMID: 35403841) JAMA Oncol. 2018 May 10;4(5):e180013. (PMID: 29543932) J Clin Med. 2020 May 11;9(5):. (PMID: 32403403) Lancet. 2017 Dec 2;390(10111):2461-2471. (PMID: 28993052) Lancet. 2021 Jul 3;398(10294):27-40. (PMID: 34102137) |
| فهرسة مساهمة: | Keywords: Borrmann type; Gastric cancer; Immunotherapy; Neoadjuvant therapy; Tumor regression grade |
| تواريخ الأحداث: | Date Created: 20240425 Latest Revision: 20240426 |
| رمز التحديث: | 20240426 |
| مُعرف محوري في PubMed: | PMC11037035 |
| DOI: | 10.4251/wjgo.v16.i4.1281 |
| PMID: | 38660643 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1948-5204 |
|---|---|
| DOI: | 10.4251/wjgo.v16.i4.1281 |